Tube LAI assay in diagnosis and monitoring of a cancer disease.
The tube leukocyte adherence inhibition (LAI) assay was used to follow the specific antitumor immunity in patients with tumors of the urogenital tract, carcinomas of the larynx, melanomas and lung tumors. Positive reactivity was observed in more than 80% of the patients with tumor, whereas less than 5% of the controls were positive. The results show that the tube LAI assay holds promise for diagnosing and monitoring cancer diseases.